| 名稱 | Nandrolone decanoate |
| 描述 | Nandrolone decanoate (19-Nortestosterone decanoate) is the decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. |
| 細(xì)胞實驗 | Cell viability is assessed one, three and five days after incubation with nandrolone decanoate at the final concentrations of 5, 10, 25 and 50 µM or the drug vehicle (1.5:1-benzyl alcohol/peanut oil), added in different amounts according to the anabolic concentrations (vehicle 5, 10, 25 and 50 µM, respectively). Together with the treatment with the anabolic steroids, 2% horse serum was added to the culture for the induction of differentiation of muscle cells. (Only for Reference) |
| 激酶實驗 | Affinity assay: The affinity of Aclidinium for the different human muscarinic receptor subtypes at equilibrium is determined by measuring their ability to displace the binding of [3H]NMS to cell membrane preparations expressing one of the human muscarinic receptor subtypes. Protein concentrations are 8.1 μg/well, 10.0 μg/well, 4.9 μg/well, 4.5 μg/well, and 5.0 μg/well for M1, M2, M3, M4, and M5 receptor membrane preparations, respectively. The assays are conducted at [3H]NMS concentrations approximately equal to the radioligand equilibrium dissociation constant (Kd) for the different muscarinic receptors subtypes. The [3H]NMS concentration is 0.3 nM for the M1 and M4 assays and 1 nM for the M2, M3, and M5 assays. A range of antagonist concentrations (10?14 to 10?5 M) are tested in duplicate to generate competition curves. Nonspecific binding is determined in the presence of atropine (1 μM). Assay reagents are dissolved in assay binding buffer (phosphate-buffered saline with calcium and magnesium) to a total volume of 200 μL. After a 2 hours or 6 hours incubation period (M1–M4 and M5, respectively) at room temperature in 96-well microtiter plates to ensure that equilibrium is achieved for Aclidinium, 150 μL aliquots of the reaction are transferred to GF/C filter plates pretreated for 1 hour with wash buffer (50 mM Tris, 100 mM NaCl, pH 7.4) containing 0.05% polyethylenimine. Bound and free [3H]NMS are then separated by rapid vacuum filtration followed by four washes with ice-cold wash buffer. Filters are then dried for 30 min before addition of 30 μL of OptiPhase Supermix, and radioactivity is quantified using a MicroBeta Trilux microplate scintillation counter. |
| 體外活性 | 在體外分化過程中，使用的濃度下，合成類固醇nandrolone decanoate無法改變肌肉細(xì)胞的活力[2]。 |
| 體內(nèi)活性 | 高劑量的nandrolone decanoate會導(dǎo)致血清葡萄糖水平下降，同時伴隨著空腹時高血清胰島素水平。nandrolone decanoate的長期給藥可減少葡萄糖產(chǎn)生率和肝糖原含量，這可能導(dǎo)致空腹血糖降低[1]。體內(nèi)研究顯示，nandrolone decanoate的效果取決于被評估的肌肉、治療時間、劑量以及是否與運動相結(jié)合。這些因素能夠增加肌肉質(zhì)量、細(xì)胞周期的變化、骨礦物質(zhì)密度、骨骼生長，并且ARs對這些效果有影響[2]。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 4.29 mg/mL (10 mM)
|
| 關(guān)鍵字 | inhibit | NMDAr | HIV | Human immunodeficiency virus | behavior | Inhibitor | glutamate | aggressive | Androgen Receptor | GLT-1 | memantine | transporter | Nandrolone decanoate |
| 相關(guān)產(chǎn)品 | Tenofovir | Valproic Acid | Chloroquine phosphate | Emtricitabine | Dolutegravir intermediate-1 | Lamivudine | 5-Fluorouracil | Decanedioic acid | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Kaempferol | Dimethyl fumarate |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 肝臟毒性化合物庫 | 抗感染化合物庫 | 抗COVID-19化合物庫 | NO PAINS 化合物庫 | FDA 上市藥物庫 | 抗病毒庫 | 藥物功能重定位化合物庫 | 人代謝物化合物庫 |